Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a SAD of CUG252 in Healthy Volunteers
NCT05328557Phase 1Completed
- Sponsor
- Cugene Inc.
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing CUG252 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events up to 10 weeks. Started Nov 2021; status: completed.
02
Drugs
CUG252
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05328557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328557.